Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice van Wijngaarden P; Qureshi SHClin Exp Optom 2008[Sep]; 91 (5): 427-37We review the fundamental changes that are now occurring to the management of neovascular (wet) age-related macular degeneration (AMD). An improved understanding of the role of vascular endothelial growth factor (VEGF) in the genesis of choroidal neovascular membranes has led to the creation and use of intravitreous anti-VEGF antibodies (bevacizumab and ranubizumab) and an aptamer (pegaptanib) in the treatment of these lesions. These new intravitreous injections for AMD have supplanted previous treatments in both efficacy and safety and are now the standard of care for neovascular AMD. We discuss the biochemistry of the anti-VEGF pathway. While there is substantial evidence for the use of ranubizumab and pegaptanib, the intravitreous administration of bevacizumab has not been tested in randomised controlled clinical trials. We review the evidence base for all three agents and the patho-physiological basis for adverse reactions to intravitreous VEGF blockade.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/adverse effects/therapeutic use[MESH]|Aptamers, Nucleotide/adverse effects/therapeutic use[MESH]|Bevacizumab[MESH]|Choroidal Neovascularization[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Macular Degeneration/*drug therapy/etiology[MESH]|Photochemotherapy[MESH]|Ranibizumab[MESH]|Vascular Endothelial Growth Factor A/*antagonists & inhibitors/physiology[MESH] |